t76312_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported):  April 23, 2013

Aceto Corporation
(Exact Name of Registrant as Specified in its Charter)


New York
000-04217
11-1720520
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
 

 

4 Tri Harbor Court, Port Washington, NY 11050
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:  (516) 627-6000



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
   
 
On April 23, 2013, Ronald Gold, President and Chief Operating Officer of Rising Pharmaceuticals Inc. (“Rising”), a wholly-owned subsidiary of Aceto Corporation (the “Company”) and David B. Rosen, Senior Vice President of Rising, informed the Company that they do not intend to remain employed with Rising subsequent to December 31, 2013, the expiration date of the three-year employment agreements entered into when they sold substantially all of the assets of their privately-owned entity to Rising.  Messrs. Gold and Rosen are actively assisting the Company with a transition plan.
   
 
The press release related to this matter is furnished as an exhibit to this report.
   
   
Item 9.01 Financial Statements and Exhibits
   
 
  
(d) Exhibits  
   
Exhibit No. Description
   
99.1  Press Release dated April 24, 2013


                                       

                    
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
ACETO CORPORATION
  
       
       
Date: April 25, 2013
By:
/s/ Salvatore Guccione  
   
Salvatore Guccione
  
   
President and Chief Executive Officer